DJDaniel Simões de Jesus

Daniel Simões de Jesus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel Simões de Jesus has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2

    by Hyun-Ju Cho, Joy Smith, Christopher H Switzer, Eleni Louka, Rebecca L Charles, Oleksandra Prysyazhna, Ewald Schroder, Mariana Fernandez-Caggiano, Daniel Simoes de Jesus, Seda Eminaga, et al.

    Activating mutations of Src homology-2 domain-containing protein tyrosine phosphatase-2 (Shp2) cause multiple childhood conditions for which there is an unmet therapeutic need, including juvenile myelomonocytic leukemia (JMML) and Noonan syndrome. SFX-01, an α-cyclodextrin-stabilized sulforaphane complex currently in clinical development, covalently adducts cysteine residues. Using unbiased proteomics, its protein targets were identified, including Shp2. SFX-01 induced an inhibitory dithiolethione modification at the Shp2 active site cysteine. Importantly, in a transgenic mouse model of human Noonan syndrome with hyperactive D61G Shp2, SFX-01 concomitantly normalized their phosphatase activity and myeloid cell count. Furthermore, SFX-01 also attenuated JMML human patient-derived hematopoietic stem cell proliferation that was linked to STAT1 signaling and decreased cyclin D1 expression, resulting in cell-cycle arrest. We conclude that SFX-01 is an activating mutant Shp2 inhibitor and may offer beneficial effects in patients with JMML or Noonan syndrome.


  • Open Access

    Effects of GLP-1 analogs combined with physical exercise on total body mass in Individuals with obesity: a systematic review

    by Ana Maria Sales Gomes Filha, Josias Melo Leite, Laura Souza Lagares, Daniel Simões de Jesus, Eric Simas Bomfim, Luiz Alberto Bastos de Almeida, Lélia Lessa Teixeira Pinto, Lucas Antônio Jesus de Souza, Clarcson Plácido Conceição dos Santos

    The literature lacks comprehensive evidence integrating results aiming to assess the combined effects of physical exercise and pharmacological therapy on body mass reduction. Therefore, this review aims to analyze the effects of glucagon-like peptide-1 (GLP-1) analogs, specifically liraglutide and semaglutide, combined with physical exercise on changes in body mass among patients with obesity. This systematic literature review is registered in PROSPERO (International Prospective Register of Systematic Reviews) under ID: CRD42023454783. Searches were conducted between September and October 2023, with no restriction on publication year and language, on the following databases: Medline via PubMed; Semantic Scholar, Web of Science, Scopus, and Embase. Nine articles involving 4,236 participants with obesity (with or without diabetes) were included. The participants were aged between 18 and 65 years and had a BMI over 27 kg/m2, being treated with liraglutide or semaglutide. Liraglutide was increased to 3.0 mg, and semaglutide to 2.4 mg. The combination of liraglutide and exercise led to an average weight loss of 5 kg over 53 weeks. Higher doses of liraglutide and semaglutide effectively reduce total body mass in individuals with obesity. Combining GLP-1 analogs with physical exercise enhances these weight loss outcomes.


  • Open Access

    Molecular aspects of COVID-19 and its relationship with obesity and physical activity: a narrative review

    by Ramon de Souza Lino, Mariana Sousa de Pina Silva, Daniel Simões de Jesus, Rodrigo Colares de Macedo, Laura Souza Lagares, Felipe Nunes Almeida dos Santos, Luiz Alberto Bastos de Almeida, Eric Simas Bomfim, Clarcson Plácido Conceição dos Santos

    BACKGROUND: Severe acute respiratory syndrome coronavirus 2 has several mechanisms of action re-lated to inflammatory responses, especially in individuals diagnosed with obesity. This hyperinflammatory clinical profile resulting from the association between obesity and coronavirus disease 2019 (COVID-19) may be attenuated by regular physical activity.OBJECTIVE: The aim of this study was to review the evidence on the consequences of physical inactivity and physical activity on COVID-19 in patients with obesity.DESIGN AND SETTING: Narrative review at the Bahiana School of Medicine and Public Health in Salvador, Brazil.METHODS: We searched evidence on the association of COVID-19 with physical activity and obesity us-ing the following keywords: "covid-19,""physical activity," and "obesity". The databases used were MEDLINE (PubMed), ScienceDirect, and Virtual Health Library. Studies published from 2019 to 2021 and available in Portuguese, English, and Spanish were included. The final search was conducted on September 26, 2021.RESULTS: We identified 661 studies in the database, among which 71 were considered for inclusion in the narrative review of the molecular aspects of COVID-19 and its relationship with physical activity and obesity.CONCLUSION: This literature review enabled the perception of the relationship between the molecular mechanisms of COVID-19 and obesity. Regular physical activity had various benefits for the inflammatory condition of the studied population, highlighting moderate-intensity..


  • Open Access

    Notch2 suppression mimicking changes in human pulmonary hypertension modulates Notch1 and promotes endothelial cell proliferation

    by Sanghamitra Sahoo, Yao Li, Daniel de Jesus, John Sembrat, Mauricio M. Rojas, Elena Goncharova, Eugenia Cifuentes-Pagano, Adam C. Straub, Patrick J. Pagano

    Pulmonary arterial hypertension (PAH) is a fatal cardiopulmonary disease characterized by increased vascular cell proliferation with apoptosis resistance and occlusive remodeling of the small pulmonary arteries. The Notch family of proteins subserves proximal signaling of an evolutionarily conserved pathway that effects cell proliferation, fate determination, and development. In endothelial cells (ECs), Notch receptor 2 (Notch2) was shown to promote endothelial apoptosis. However, a pro- or antiproliferative role for Notch2 in pulmonary endothelial proliferation and ensuing PAH is unknown. We postulated that suppressed Notch2 signaling drives pulmonary endothelial proliferation in the context of PAH. We observed that levels of Notch2 are ablated in lungs from PAH subjects compared with non-PAH controls. Notch2 expression was attenuated in human pulmonary artery endothelial cells (hPAECs) exposed to vasoactive stimuli including hypoxia, TGF-β, ET-1, and IGF-1. Notch2-deficient hPAECs activated Akt, Erk1/2, and antiapoptotic protein Bcl-2 and reduced levels of p21cip and Bax associated with increased EC proliferation and reduced apoptosis. In addition, Notch2 suppression elicited a paradoxical activation of Notch1 and canonical Notch target gene Hes1, Hey1, and Hey2 transcription. Furthermore, reduction in Rb and increased E2F1 binding to the Notch1 promoter appear to explain the Notch1 upregulation. Yet, when Notch1 was decreased in Notch2-suppressed cells, the wound injury response was augmented. In aggregate, our results demonstrate that loss of Notch2 in hPAECs derepresses Notch1 and elicits EC hallmarks of PAH. Augmented EC proliferation upon Notch1 knockdown points to a context-dependent role for Notch1 and 2 in endothelial cell homeostasis. NEW & NOTEWORTHY This study demonstrates a previously unidentified role for Notch2 in the maintenance of lung vascular endothelial cell quiescence and pulmonary artery hypertension (PAH). A key novel finding is that Notch2 suppression activates Notch1 via Rb-E2F1-mediated signaling and induces proliferation and apoptosis resistance in human pulmonary artery endothelial cells. Notably, PAH patients show reduced levels of endothelial Notch2 in their pulmonary arteries, supporting Notch2 as a fundamental driver of PAH pathogenesis.


  • Open Access

    G-quadruplex dynamics contribute to regulation of mitochondrial gene expression

    by M. Falabella, J. E. Kolesar, C. Wallace, D. de Jesus, L. Sun, Y. V. Taguchi, C. Wang, T. Wang, I. M. Xiang, J. K. Alder, et al.

    Single-stranded DNA or RNA sequences rich in guanine (G) can adopt non-canonical structures known as G-quadruplexes (G4). Mitochondrial DNA (mtDNA) sequences that are predicted to form G4 are enriched on the heavy-strand and have been associated with formation of deletion breakpoints. Increasing evidence supports the ability of mtDNA to form G4 in cancer cells; however, the functional roles of G4 structures in regulating mitochondrial nucleic acid homeostasis in non-cancerous cells remain unclear. Here, we demonstrate by live cell imaging that the G4-ligand RHPS4 localizes primarily to mitochondria at low doses. We find that low doses of RHPS4 do not induce a nuclear DNA damage response but do cause an acute inhibition of mitochondrial transcript elongation, leading to respiratory complex depletion. We also observe that RHPS4 interferes with mtDNA levels or synthesis both in cells and isolated mitochondria. Importantly, a mtDNA variant that increases G4 stability and anti-parallel G4-forming character shows a stronger respiratory defect in response to RHPS4, supporting the conclusion that mitochondrial sensitivity to RHPS4 is G4-mediated. Taken together, our results indicate a direct role for G4 perturbation in mitochondrial genome replication, transcription processivity, and respiratory function in normal cells.


  • Open Access

    Nox1/Ref-1-mediated activation of CREB promotes Gremlin1-driven endothelial cell proliferation and migration

    by Daniel S. de Jesus, Evan DeVallance, Yao Li, Micol Falabella, Danielle Guimaraes, Sruti Shiva, Brett A. Kaufman, Mark T. Gladwin, Patrick J. Pagano


  • Open Access

    NADPH oxidase 2 inhibitors CPP11G and CPP11H attenuate endothelial cell inflammation & vessel dysfunction and restore mouse hind-limb flow

    by Y. Li, E. Cifuentes-Pagano, E.R. DeVallance, D.S. de Jesus, S. Sahoo, D.N. Meijles, D. Koes, C.J. Camacho, M. Ross, C. St Croix, et al.


  • Endothelial Nox1 oxidase assembly in human pulmonary arterial hypertension; driver of Gremlin1-mediated proliferation

    by Imad Al Ghouleh, Sanghamitra Sahoo, Daniel N. Meijles, Jefferson H. Amaral, Daniel S. de Jesus, John Sembrat, Mauricio Rojas, Dmitry A. Goncharov, Elena A. Goncharova, Patrick J. Pagano

    Pulmonary arterial hypertension (PAH) is a rapidly degenerating and devastating disease of increased pulmonary vessel resistance leading to right heart failure. Palliative modalities remain limited despite recent endeavors to investigate the mechanisms underlying increased pulmonary vascular resistance (PVR), i.e. aberrant vascular remodeling and occlusion. However, little is known of the molecular mechanisms responsible for endothelial proliferation, a root cause of PAH-associated vascular remodeling. Lung tissue specimens from PAH and non-PAH patients and hypoxia-exposed human pulmonary artery endothelial cells (ECs) (HPAEC) were assessed for mRNA and protein expression. Reactive oxygen species (ROS) were measured using cytochrome c and Amplex Red assays. Findings demonstrate for the first time an up-regulation of NADPH oxidase 1 (Nox1) at the transcript and protein level in resistance vessels from PAH compared with non-PAH patients. This coincided with an increase in ROS production and expression of bone morphogenetic protein (BMP) antagonist Gremlin1 (Grem1). In HPAEC, hypoxia induced Nox1 subunit expression, assembly, and oxidase activity leading to elevation in sonic hedgehog (SHH) and Grem1 expression. Nox1 gene silencing abrogated this cascade. Moreover, loss of either Nox1, SHH or Grem1 attenuated hypoxia-induced EC proliferation. Together, these data support a Nox1-SHH-Grem1 signaling axis in pulmonary vascular endothelium that is likely to contribute to pathophysiological endothelial proliferation and the progression of PAH. These findings also support targeting of Nox1 as a viable therapeutic option to combat PAH.


  • Open Access

    Circadian control of β ‐cell function and stress responses

    by J. Lee, R. Liu, D. de Jesus, B. S. Kim, K. Ma, M. Moulik, V. Yechoor

    Circadian disruption is the bane of modern existence and its deleterious effects on health; in particular, diabetes and metabolic syndrome have been well recognized in shift workers. Recent human studies strongly implicate a ‘dose‐dependent’ relationship between circadian disruption and diabetes. Genetic and environmental disruption of the circadian clock in rodents leads to diabetes secondary to β‐cell failure. Deletion of Bmal1 , a non‐redundant core clock gene, leads to defects in β‐cell stimulus‐secretion coupling, decreased glucose‐stimulated ATP production, uncoupling of OXPHOS and impaired glucose‐stimulated insulin secretion. Both genetic and environmental circadian disruptions are sufficient to induce oxidative stress and this is mediated by a disruption of the direct transcriptional control of the core molecular clock and Bmal1 on Nrf2, the master antioxidant transcription factor in the β‐cell. In addition, circadian disruption also leads to a dysregulation of the unfolded protein response and leads to endoplasmic reticulum stress in β‐cells. Both the oxidative and endoplasmic reticulum ( ER ) stress contribute to an impairment of mitochondrial function and β‐cell failure. Understanding the basis of the circadian control of these adaptive stress responses offers hope to target them for pharmacological modulation to prevent and mitigate the deleterious metabolic consequences of circadian disruption.


  • Open Access

    DHEA supplementation in ovariectomized rats reduces impaired glucose‐stimulated insulin secretion induced by a high‐fat diet

    by Katherine Veras, Felipe Natali Almeida, Renato Tadeu Nachbar, Daniel Simões de Jesus, João Paulo Camporez, Ângelo Rafael Carpinelli, Julia H. Goedecke, Carla Roberta de Oliveira Carvalho

    Dehydroepiandrosterone (DHEA) and the dehydroepiandrosterone sulfate (DHEA‐S) are steroids produced mainly by the adrenal cortex. There is evidence from both human and animal models suggesting beneficial effects of these steroids for obesity, diabetes mellitus, hypertension, and osteoporosis, conditions associated with the post‐menopausal period. Accordingly, we hypothesized that DHEA supplementation in ovariectomized (OVX) female rats fed a high‐fat diet would maintain glucose‐induced insulin secretion (GSIS) and pancreatic islet function. OVX resulted in a 30% enlargement of the pancreatic islets area compared to the control rats, which was accompanied by a 50% reduction in the phosphorylation of AKT protein in the pancreatic islets. However, a short‐term high‐fat diet induced insulin resistance, accompanied by impaired GSIS in isolated pancreatic islets. These effects were reversed by DHEA treatment, with improved insulin sensitivity to levels similar to the control group, and with increased serine phosphorylation of the AKT protein. These data confirm the protective effect of DHEA on the endocrine pancreas in a situation of diet‐induced overweight and low estrogen concentrations, a phenotype similar to that of the post‐menopausal period.